Archived Comments for:
Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials
Petra Leyendecker, Mundipharma Research GmbH & Co. KG
7 December 2010
After the publication of this work it was brought to our attention that on page 4, in the first paragraph of Results section, the values for the rates of discontinuation of the two treatment groups have been transposed in error. The sentence should read: "Similar rates of study drug discontinuation were observed in the two treatment groups: 16.3 and 13.7%, respectively, in the oxycodone PR and the oxycodone PR/naloxone PR groups."
In Figure 3 on page 7, the symbols used in the key for the graph have been erroneously transposed. The correct key should be the black circle and solid line symbol for “Oxycodone PR/naloxone PR”, and the black diamond and dashed line symbol for “Oxycodone PR”
We regret any confusion that these errors may have caused, and thank our colleagues for bringing it to our attention.
Minor Correction
7 December 2010
After the publication of this work it was brought to our attention that on page 4, in the first paragraph of Results section, the values for the rates of discontinuation of the two treatment groups have been transposed in error. The sentence should read: "Similar rates of study drug discontinuation were observed in the two treatment groups: 16.3 and 13.7%, respectively, in the oxycodone PR and the oxycodone PR/naloxone PR groups."
In Figure 3 on page 7, the symbols used in the key for the graph have been erroneously transposed. The correct key should be the black circle and solid line symbol for “Oxycodone PR/naloxone PR”, and the black diamond and dashed line symbol for “Oxycodone PR”
We regret any confusion that these errors may have caused, and thank our colleagues for bringing it to our attention.
Competing interests
None